Amgen (AMGN) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · United States · ISIN US0311621009
Amgen financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 36.75 bn USD |
| Gross profit | 24.71 bn USD |
| Operating income | 9.08 bn USD |
| EBIT | 11.32 bn USD |
| Net income | 7.71 bn USD |
| Diluted EPS – continuing operations | 14.23 USD |
Full history since 1985, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
More stocks
- Siemens (SIE.DE)
- CNOOC Limited (600938.SS)
- Wells Fargo (WFC)
- Kweichow Moutai Co Ltd (600519.SS)
- L'Oreal SA (OR.PA)
- KLA Corporation (KLAC)
- Toyota Motor Corporation ADR (TM)
- Citigroup (C)
- Linde plc (LIN)
- SHOPIFY INC. (SHOP)
- LVMH Moet Hennessy Louis Vuitton SE (MC.PA)
- IBM (IBM)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.